Search results
Results from the WOW.Com Content Network
Atezolizumab, sold under the brand name Tecentriq among others, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma and alveolar soft part sarcoma, [9] [11] but discontinued for use in triple-negative breast cancer (TNBC). [12]
The subcutaneous injection of atezolizumab and hyaluronidase was evaluated in IMscin001 (NCT03735121), an open-label, multi-center, international, randomized trial in adults with locally advanced or metastatic non-small cell lung cancer who were not previously exposed to cancer immunotherapy and who had disease progression following treatment with platinum-based chemotherapy. [2]
Currently, many PD-1 inhibitors are under development: [7] Vopratelimab (JTX-4014) by Jounce Therapeutics [21] As of 2020 entered Phase I trial [22] Spartalizumab (PDR001) is a PD-1 inhibitor developed by Novartis to treat both solid tumors and lymphomas, which as of 2018 has entered Phase III trials. [23] [24] [25]
The US Food and Drug Administration (FDA) approved durvalumab for certain types of bladder, lung, and biliary tract cancer: [6] [13] [14]. Adults with locally advanced or metastatic urothelial carcinoma who either have disease progression during or following platinum-containing chemotherapy or have disease progression within twelve months of neoadjuvant or adjuvant treatment with platinum ...
The Academy of Sciences of Albania (Albanian: Akademia e Shkencave e Shqipërisë), founded in 1972, is the most important scientific institution in Albania. [1] In the 1980s, several research institutes began at the University of Tirana were transferred to the Academy's jurisdiction. [ 2 ]
Channel 2, Albania Top News is a 24-hour Albanian television news channel that first aired on February 12, 2007. [ 2 ] It is a sister to, and owned by Top Channel , by association its parent company Top Media Group . [ 1 ]
9 to 25 February – Albania participated at the 2018 Winter Olympics in PyeongChang, South Korea, with 2 competitors in 1 sport (alpine skiing). Deaths [ edit ]
[7] Phase III clinical trials produced mixed results; and, on October 14, 2020, Hoffmann-La Roche, the parent company of Genentech, abandoned further efforts to develop etrolizumab for ulcerative colitis, but continued development for Crohn's disease, [8] until disappointing trial results led to this being abandoned too in February 2022. [9]